 |
 |
|
member of Nordic Center of Excellence in Neurodegenration. The percentage of extramural funding in Kuopio University is among the highest among Finnish Universties. The Insitute also hold a status of Center of Excellence in teaching. Kuopio has carried out the first Nordic clinical trials on gene therapy. More than 5 successful spin off biocompanies have been established durin the last 7 years by the institute, one of them, Ark Therpaeutics, is the world leader in gene therapy. Professor Jari Koistinaho is Dean of the Insitute, Head of the Kuopio Biocenter, and a board member of Biocenter Finland and the Nordic Center of Exellence in Neurodegeneration. He has published over 150 original articles on neurodegeneration in international scientific journals. His group made the original finding on neuroprotective effect of minocycline which has triggered several clinical trials in the US and other countries. The institute has core facilities for non-invasive imaging (MRI and SPECT/CT), modern behavioural research unit, GLP laboratories for various constructs and viruses for gene therapy, gene array and proteomics units. Together with Kuopio University Hospital the researcher carry out clinical trials on stroke and other brain diseases.
Role in ProjectThe Kuopio team contributes to the project by investigating the role of aging, apoliprotein E isoforms and different co-morbidities in stroke models, identifying novel inflammatory targets in stroke, identifying novel neuroprotective antibiotics and their derivatives, and by developing novel mouse models and their non-invasive imaging for the project. In addition, Kuopio coordinates the training WP (WP9). Project Leader
Project Staff
|
